We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals

96 hedge funds and large institutions have $143M invested in X4 Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more capital invested

Capital invested by funds: $81.5M → $143M (+$61.7M)

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

15% more call options, than puts

Call options by funds: $705K | Put options by funds: $611K

3% more funds holding

Funds holding: 9396 (+3)

0.11% more ownership

Funds ownership: 1.94%2.04% (+0.11%)

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

Holders
96
Holders Change
+3
Holders Change %
+3.23%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
14
Increased
23
Reduced
24
Closed
11
Calls
$705K
Puts
$611K
Net Calls
+$94K
Net Calls Change
+$325K
Name Holding Trade Value Shares
Change
Change in
Stake
XT
101
XTX Topco
Cayman Islands
-$57.9K -2,303 Closed
Squarepoint
102
Squarepoint
New York
-$54.3K -2,159 Closed
BCM
103
Bayesian Capital Management
New York
-$33K -1,313 Closed
State Board of Administration of Florida Retirement System
104
State Board of Administration of Florida Retirement System
Florida
-$26.8K -1,066 Closed
HF
105
HRT Financial
New York
-$14K -569 Closed
SG
106
StoneX Group
New York
-$9.85K -392 Closed
MWM
107
Mission Wealth Management
California
-$8.38K -333 Closed
Simplex Trading
108
Simplex Trading
Illinois
-$890 -32 Closed

XFOR Hedge Fund Activity: Q1 2024 in Review

96 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2024, worth a combined $143M — up 76% from $81.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new XFOR positions and 11 closed out — a net gain of 3 holders — while 23 added to existing stakes and 24 trimmed.

The largest buyer was Soleus Capital Management, opening a new position worth an estimated $4.25M. The largest seller was Armistice Capital, exiting entirely with an estimated $1.62M sold.

  • 96 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2024, up from 93 in Q4 2023.
  • Funds reported $143M of X4 Pharmaceuticals stock for Q1 2024, up 76% quarter-over-quarter.
  • 14 funds opened new X4 Pharmaceuticals positions in Q1 2024 and 11 closed out, a net change of +3 holders.
  • The largest X4 Pharmaceuticals buyer in Q1 2024 was Soleus Capital Management, an estimated $4.25M added.
  • The largest X4 Pharmaceuticals seller in Q1 2024 was Armistice Capital, an estimated $1.62M sold.

Based on aggregated 13F filings for Q1 2024.